Bibliographic Details
| Title: |
Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone receptor antagonist, in healthy men: a randomized, double-blind, placebo-controlled phase 1 study. |
| Authors: |
Li, Xin1 (AUTHOR), Sun, Feifei1 (AUTHOR), Zhang, Xiaolei1 (AUTHOR), Lin, Pingping1 (AUTHOR), Shen, Kai2 (AUTHOR), Shen, Yu2 (AUTHOR), Ma, Lingyu2 (AUTHOR), Cao, Yu1 (AUTHOR) caoyu@qdu.edu.cn, Wang, Chenjing1 (AUTHOR) wangchenjing@qdu.edu.cn |
| Superior Title: |
BMC Medicine. 4/3/2023, Vol. 21 Issue 1, p1-10. 10p. |
| Subject Terms: |
*LUTEINIZING hormone releasing hormone receptors, *HORMONE antagonists, *PHARMACODYNAMICS, *GONADOTROPIN releasing hormone, *ANDROGEN deprivation therapy |
| Abstract: |
Background: Gonadotropin-releasing hormone (GnRH) antagonists are a promising therapeutic approach for treating hormone-dependent prostate cancer. Currently, the mainstream GnRH antagonists are polypeptide agents administered through subcutaneous injection. In this study, we evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SHR7280, an oral small molecule GnRH antagonist, in healthy men. Methods: This phase 1 trial was a randomized, double-blind, placebo-controlled, and dose-ascending study. Eligible healthy men were randomized in a 4:1 ratio to receive either oral SHR7280 tablets or placebo twice daily (BID) for 14 consecutive days. The SHR7280 dose was initiated at 100 mg BID and then sequentially increased to 200, 350, 500, 600, 800, and 1000 mg BID. Safety, PK, and PD parameters were assessed. Results: A total of 70 subjects were enrolled and received the assigned drug, including 56 with SHR7280 and 14 with placebo. SHR7280 was well-tolerated. The incidence of adverse events (AEs, 76.8% vs 85.7%) and treatment-related AEs (75.0% vs 85.7%), as well as the severity of AEs (moderate AEs, 1.8% vs 7.1%) were similar between the SHR7280 group and placebo group. SHR7280 was rapidly absorbed in a dose-dependent manner, with a median Tmax of each dose group ranging from 0.8 to 1.0 h on day 14 and a mean t1/2 ranging from 2.8 to 3.4 h. The PD results demonstrated that SHR7280 exhibited a rapid and dose-proportional suppression of hormones, including LH, FSH, and testosterone, with maximum suppression achieved at doses of 800 and 1000 mg BID. Conclusions: SHR7280 showed an acceptable safety profile, as well as favorable PK and PD profiles within a dose range of 100 to 1000 mg BID. This study proposes a rationale for further investigation of SHR7280 as a potential androgen deprivation therapy. Trial registration: Clinical trials.gov NCT04554043; registered September 18, 2020. [ABSTRACT FROM AUTHOR] |
|
Copyright of BMC Medicine is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Premier |
|
Full text is not displayed to guests. |
Login for full access.
|